Case Report
Neutropenia due to Tacrolimus in a Cadaveric Renal Transplant Patient
Yelda Deligöz Bildacı1, Ömer Celal Elçioğlu1, Yunus Taşçı2, Meltem Gürsu1 and Rümeyza Kazancıoğlu1*
1Department of Nephrology, Bezmialem University, Turkey
2Bezmialem University, General Surgery Department, Turkey
*Corresponding author: Rümeyza Kazancıoğlu, Department of Nephrology, Bezmialem University, Fatih / İstanbul /Turkey
Published: 06 Dec, 2016
Cite this article as: Bildacı YD, Elçioğlu ÖC, Taşçı Y, Gürsu
M, Kazancıoğlu R. Neutropenia due
to Tacrolimus in a Cadaveric Renal
Transplant Patient. Ann Clin Case Rep.
2016; 1: 1203.
Abstract
Myelosuppression is known to occur in kidney transplant recipients because of widely used immunosuppressant chemotherapeutic agents. Myelosuppression usually results with leukopenia and less often with neutropenia representing with percentages of 10 to 55% and 4.9 to 37.5% respectively [1,2]. Bone marrow toxicity caused by medications, systemic infections or posttransplant lymphoproliferative disease are the possible etiology of neutropenia. Also neutropenia can both be the result of decreased neutrophil production from inefficient granulopoesis because of afore-mentioned reasons or increased peripheral destruction. Tacrolimus, which is one of the most important part of kidney transplantation immunosuppressive protocols, has a very rare effect of myelosuppression other than metabolic side effects which are more common. In this case report we aimed to describe a patient with severe neutropenia developed six months after a cadaveric renal transplantation.
Case Presentation
A 42-years-old woman with end stage renal failure due to unknown etiology, who is on
continuous ambulatory peritoneal dialysis treatment, underwent cadaveric kidney transplantation
on November 2015. Laboratory values including haemoglobulin, leucocyte and platelet counts were
completely normal at the time of transplantation.
Right after transplantation Anti-Thymocyte Globulin (ATG) induction was initiated with
triple immunosuppressive regimen including tacrolimus, mycophenolate mofetil (MMF) and
prednisolone. Patient was discharged with full recovery sent home with adding fluconazole,
trimethoprim-sulfamethoxazole (TMP) and valganciclovir for infection prophylaxis.
On the 50th day of transplantation, leukopenia detected with leucocyte count of 2800 / mm3
(normal range 4.000-10.000/mm3). Viral infections including cytomegalovirus, parvovirus B19
were excluded with appropriate testing. MMF dose was reduced from 1000 mg/day to 500 mg/day.
Following achieving normal leucocyte count on a week follow up, MMF dose were increased back
to 1000 mg/day. Fluconazole and valganciclovir therapies were stopped on day 90 according to our
department’s transplantation follow up protocol. On 104th day of transplantation, BK virus PCR
was found to be positive in both blood and urine samples as 1027 copies/ml and 868.120 copies/ml
respectively, so then she was put on levofloxacin therapy.
On 220th day of transplantation while patient was still on prednisolone 5 mg/day, a constant level
of tacrolimus achieved as 4-6 ng/ml, MMF 1.000 mg/day, TMP and levofloxacin, she was subjected
to an ovarian cyst operation to rule out a possible malignancy. On the 3rd day of ovarian operation
leucocyte count and neutrophil count as 2.200/mm3and 1.100/mm3 (normal range 1.500-9.000/
mm3) respectively, resulted with immediate cessation of MMF and TMP therapies. Parvovirus B19
testing came back negative and cytomegalovirus PCR testing resulted as low tittered positive (2.300
copies/ml). Two days after immediate initiation of valganciclovir, neutrophil count decreased to 20/
mm3 leading to cessation of levofloxacin which thought as a possible reason for neutropenia. Bone
marrow aspiration and biopsy examination revealed neither malignancy nor a finding suggesting
cytomegalovirus infection. Following having a second result on cytomegalovirus PCR which was
negative, and finding out that bone marrow was hypo-cellular, valganciclovir was stopped after 7
days.
Patient responded to changing tacrolimus therapy with cyclosporine therapy in two days.
Leucocyte count increased from 1.600/mm3 to 2.600/mm3 and
neutrophil count increased from 20/mm3 to 530/mm3in four days.
MMF was restarted after a month of clinical alleviation. Following
two months did not make any change on leucocyte count which
were 4.300/mm3 and neutrophil count which were 3.300/mm3.
Patient’s renal functions had not been deteriorated throughout the
neutropenic period.
Discussion
Immunosuppressant’s such as MMF, ATG, tacrolimus and
azathioprine are indicated for post kidney transplantation phase.
They have lots of common and from time to time life threatening side
effects such as myelosuppression [1,2]. Other supportive drugs like
omeprazole, angiotensin converting enzyme inhibitor, valgancyclovir
and TMP reported as causes for neutropenia. A retrospective study
in kidney recipients reported MMF-tacrolimus combination therapy
was associated with a 28% chance of neutropenia in the first year
period of transplantation [3]. It is really hard to establish a link
between possible causes and myelosuppression with conventional
testing methods so clinicians usually rule out other factors like
infections and malignancies first and then medications are stopped to
increase neutrophil count [4].
Cyclosporine and tacrolimus are both effective with inhibition
of calcineurin-mediated T-cell receptor signal transduction and
inhibition of interleukin-2 (IL-2) transcription [5]. When compared
in efficacy, tacrolimus is found to reduce risk of acute rejection and
steroid resistant rejection [6].
The causative link between tacrolimus and myelosuppression is
not clear [7]. There is a hypothesis expressing the fact that it could stop
maturation in myeloid precursor cells. However in vitro experiments,
has shown this hypothesis is not true [8,9]. Likewise other published
case reports and our case report had bone marrow biopsy done, with
results revealing no clue for maturation arrest [4].
Cytokines produced by lymphocytes or monocytes inhibiting
granulopoesis and increasing apoptosis is an another hypothesis for
tacrolimus induced neutropenia [4]. Hirao et al. [8], experimented
adding antibodies against these cytokines resulted with no differences
in myeloid progenitor cell colony forming units. In a third hypothesis,
tacrolimus was thought to increase mycophenolic acid (MPA)
bioavailability as with another study it was demonstrated that MPA
when used as combination therapy with cyclosporine found out to
have lower serum concentration [10]. Even though we think that
this might be the correct pathway to understand tacrolimus induced
neutropenia, all cases found in literature and also our case showed
persistence of neutropenia even though MMF was discontinued.
Another hypothesis is formation of antibodies against myeloid
precursors or mature neutrophils. However, not a single study was
able to confirm the presence of antibodies [11]. In our case following
exclusion of all well-known reasons of neutropenia in a kidney
transplant recipient, chancing tacrolimus to cyclosporine seemed to
do the trick.
Conclusion
Even though MMF is the drug accused of neutropenia in kidney transplant recipients, myelosuppression can be because of an extremely rare side effect of tacrolimus. There are only a few cases reported in literature about this phenomenon so clinicians should keep tacrolimus in mind as a possible reason for neutropenia.
References
- Rerolle JP, Szelag JC, Le Meur Y. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and val-ganciclovir in kidney transplant recipients. Nephrol Dial Transplant. 2007; 22: 671-672.
- Chen IM, Chang HH, Hsu CP, Lai ST, Hsieh YC, Shih CC. Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in chinese cardiac recipients. Circ J. 2007; 71: 968-972.
- Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am J Transplant. 2009; 9: 1816-1825.
- De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin J Am Soc Nephrol. 2011: 6: 690-694.
- Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J. 1997; 73: 386-390.
- Margreiter R, European Tacrolimus vs Cyclosporine Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: a randomized multicentre study. Lancet. 2002; 359: 741.
- Dobrolet NC, Webber SA, Blatt J, Michaels M, KiaffasM, Kurland G, et al. Hematologic abnormalities in childrenand young adults receiving tacrolimus-based immunosuppression following cardiothoracic transplantation. Pediatr Transplant. 2001; 5: 125-131.
- Hirao A, Kawano Y, Takaue Y. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. Blood. 1993; 81: 1179-1183.
- Koenig JM, Matharoo N, Stegner JJ, Schowengerdt KO. Tacrolimus: In vitroeffects on myelopoiesis, apoptosis, andCD11b expression. J Heart Lung Transplant. 2005; 24: 1332-1336.
- Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis AMiller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit. 1999; 21: 35-43.
- Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346: 995-1008.